Russell Investments Group Ltd. lessened its stake in Teladoc Inc (NYSE:TDOC) by 16.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,904 shares of the health services provider’s stock after selling 16,417 shares during the period. Russell Investments Group Ltd. owned 0.12% of Teladoc worth $4,754,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. We Are One Seven LLC boosted its stake in shares of Teladoc by 241.1% during the first quarter. We Are One Seven LLC now owns 2,845 shares of the health services provider’s stock worth $115,000 after buying an additional 2,011 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Teladoc by 68.8% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,874 shares of the health services provider’s stock worth $116,000 after buying an additional 1,171 shares during the period. Rockefeller Capital Management L.P. acquired a new stake in shares of Teladoc during the first quarter worth about $154,000. Garner Asset Management Corp acquired a new stake in shares of Teladoc during the second quarter worth about $200,000. Finally, Pier 88 Investment Partners LLC acquired a new stake in shares of Teladoc during the second quarter worth about $201,000.
In other Teladoc news, SVP Andrew Turitz sold 13,821 shares of the stock in a transaction dated Tuesday, July 3rd. The shares were sold at an average price of $59.43, for a total value of $821,382.03. Following the completion of the transaction, the senior vice president now directly owns 9,378 shares of the company’s stock, valued at $557,334.54. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Adam C. Vandervoort sold 5,550 shares of the stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $77.67, for a total transaction of $431,068.50. Following the completion of the transaction, the insider now directly owns 2,934 shares of the company’s stock, valued at $227,883.78. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 242,497 shares of company stock valued at $16,108,269. 3.95% of the stock is currently owned by corporate insiders.
Teladoc (NYSE:TDOC) last issued its earnings results on Wednesday, August 1st. The health services provider reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.01. Teladoc had a negative net margin of 37.78% and a negative return on equity of 19.10%. The company had revenue of $94.60 million during the quarter, compared to analysts’ expectations of $91.56 million. During the same period last year, the company posted ($0.28) earnings per share. The firm’s quarterly revenue was up 112.1% compared to the same quarter last year. sell-side analysts predict that Teladoc Inc will post -1.51 earnings per share for the current year.
TDOC has been the subject of several recent research reports. Jefferies Financial Group set a $74.00 target price on shares of Teladoc and gave the stock a “buy” rating in a research note on Wednesday, July 11th. Citigroup increased their target price on shares of Teladoc to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, June 5th. SunTrust Banks increased their price target on shares of Teladoc from $48.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, June 5th. Canaccord Genuity increased their price target on shares of Teladoc from $47.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, June 5th. Finally, Craig Hallum raised shares of Teladoc from a “hold” rating to a “buy” rating in a report on Tuesday, June 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Teladoc currently has a consensus rating of “Buy” and a consensus price target of $65.10.
Teladoc Company Profile
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Read More: Asset Allocation and Your Retirement
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Inc (NYSE:TDOC).
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.